Optimizing Melphalan Pharmacokinetics in Regional Melanoma Therapy: Does Correcting for Ideal Body Weight Alter Regional Response or Toxicity?

Por McMahon, N., Cheng, T. Y., Beasley, G. M., Spasojevic, I., Petros, W., Augustine, C. K., Zipfel, P., Padussis, J. C., Sanders, G., Tyler, Douglas S.
Publicado em 2009

A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the Extremity

Por Beasley, G. M., Coleman, A. P., Raymond, A., Sanders, G., Selim, M. A., Peterson, B. L., Brady, M. S., Davies, M. A., Augustine, C., Tyler, D. S.
Publicado no Ann Surg Oncol (2012)